Vivet Therapeutics is pleased to announce that our CEO, Jean-Philippe Combal, will be attending the Jefferies Global Healthcare Conference in London from November 18th to 20th, 2025.

As we join this leading global event, we are excited to present our latest advances, including the VTX-PID NAb depleting strategy. VTX-PID is designed to temporarily reduce anti-AAV neutralizing antibodies, allowing for safe and effective AAV-based gene therapy even in individuals who previously had inhibitory antibody levels. Recent results demonstrate that, by enabling a greater proportion of the population to become eligible for AAV gene therapies, our model and PK/PD approach represents a breakthrough in overcoming the historical barrier of pre-existing immunity.

This means that many more patients—once excluded due to naturally occurring NAbs—could benefit from future AAV gene therapy innovations. Our evidence-based, targeted intervention has been validated with both dose-ranging and PK/PB modeling data, supporting clinical translation across multiple indications and AAV serotypes.

If you are attending Jefferies in London, we look forward to connecting and discussing how expanding access to transformative gene therapies can improve patient outcomes for broader populations.